Researcher Spotlight: Maria White, PhD The university of north carolina at chapel hill Epstein-Barr virus (EBV) is a common human pathogen that has been linked to the development of many types of cancers, including lymphoma. EBV-associated lymphomas are aggressive and…
Researcher Spotlight: Pierre Stéphan, MD, PhD brigham and women’s hospital Patients diagnosed with angioimmunoblastic T-cell lymphoma (AITL) face poor prognosis and limited treatment options. “We believe this is partly due to a lack of understanding of the complex set of…
Researcher Spotlight: Paurnima Patil, PhD memorial sloan kettering cancer center Oliver W. Press, MD, PhD, Memorial Fellow Dr. Patil’s research has identified a gene (ARHGEF2) that is multiplied in many cases of diffuse large B-cell lymphoma (DLBCL). The protein encoded…
Researcher Spotlight: Priya Lakra, PhD md anderson cancer center Health Equity Initiative Chromatin remodeling complexes known as BAF complexes are responsible for regulating gene expression and play important roles in the normal development of B cells. Expression of the different…
Researcher Spotlight: Daniela Magliulo, PhD weill cornell medicine Chromatin refers to DNA and protein complexes that form 3-dimensional structures within the genome. These structures can bring together genetic elements across long stretches of DNA or even between different chromosomes to…
Researcher Spotlight: Tianfang Ma, PhD Dana-farber cancer institute Health Equity Initiative Immunotherapies that activate the immune system against cancer cells have yielded promising results for many patients with diffuse large B-cell lymphoma (DLBCL), but not all people respond to treatment.…
Researcher Spotlight: Etienne Leveille, MD yale university Ferroptosis is a type of cell death to which therapy-resistant cancer cells have been found to be highly sensitive. Lymphomas, including diffuse large B-cell lymphoma (DLBCL), are among the most ferroptosis-sensitive types of…
Researcher Spotlight: Michelle Lee, MD, PhD emory university Black patients with diffuse large B-cell lymphoma (DLBCL) tend to have worse outcomes than patients from other groups. These differences may be due to a combination of biological and genetic factors, but…
Researcher Spotlight: Kazuya Fukasawa, PhD memorial sloan kettering cancer center Condon Family Fellow The introduction of bispecific antibodies represents a promising therapeutic advancement in the treatment of lymphoma. These therapies work by redirecting T-cells to interact with tumor cells, supporting…
Researcher Spotlight: Pantaleo De Simone, MD columbia university irving medical center Diffuse large B-cell lymphoma (DLBCL) is an aggressive and often incurable form of lymphoma. An improved understanding of DLBCL biology is needed to identify potential treatment strategies, and Dr.…
